All In Biotech

Free tool

FAERS Monitor: Taytulla

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 204426 or its brand name (Taytulla, Ethinyl Estradiol, Norethindrone Acetate). Reports on generic versions are filed under their own applications.

Reports

318

Serious

73

23% of reports

Hospitalization

25

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use45
  • drug ineffective34
  • recalled product administered34
  • nausea20
  • pregnancy20
  • headache16
  • metrorrhagia16
  • product dose omission13
  • pruritus13
  • anxiety11
  • dizziness9
  • pregnancy on oral contraceptive9
  • product use issue9
  • recalled product9
  • vomiting9

Reports by year received

View as table
YearReports
20124
20165
201717
201893
201996
202048
202127
20229
20238
20245
20256

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,841 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
recalled productSignal9345.8181.32,745
recalled product administeredSignal34236.6172.17,720
pregnancy on oral contraceptiveSignal9227.9119.51,806
pregnancySignal2066.143.31,219
metrorrhagiaSignal1662.138.5902
product dose omissionSignal1313.27.7135
off label useSignal453.42.677
product use issueSignal93.21.711
anxietySignal112.61.49
pruritusSignal132.21.38
drug ineffective341.71.210
headache161.71.04
nausea201.71.15
vomiting91.30.70
dizziness91.20.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.